# Jenny Rooke

> Jenny Rooke is a Series A investor at Genoa Ventures backing Biotechnology and Health Care. See 27 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Genoa Ventures](https://shizune.co/investors/profile/5-prime-ventures)
- Location: San Francisco, United States
- Total investments: 27
- Last investment: Mar 2026
- Lead investor: 33%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/jennyrooke/
- X (Twitter): https://www.twitter.com/drjennyrooke
- Website: https://www.genoavc.com

Jenny Rooke is a Series A investor at Genoa Ventures in San Francisco focused on Biotechnology and Health Care. Dr. Jenny Rooke is the Founder and Managing Director of Genoa Ventures.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 15 | 56% |
| Health Care | 7 | 26% |
| Pharmaceutical | 4 | 15% |
| Health Diagnostics | 4 | 15% |
| Medical | 3 | 11% |

30 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 8 | 30% |
| Series B | 7 | 26% |
| Seed | 4 | 15% |
| Series C | 4 | 15% |
| Funding Round | 3 | 11% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 16 | 59% |
| France | 1 | 4% |
| United Kingdom | 1 | 4% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Tropic Biosciences | At Tropic Biosciences, They develop high-performing commercial varieties of tropical crops which promote grower wellbeing, consumer health, and improved sustainable environmental practices, using cutting edge non-GMO gene editing techniques. | $105M | Series C | Mar 12, 2026 |  |
| BrightSpec | LabBrightSpec addresses high-value, time-sensitive analytical chemistry challenges that are not well addressed by other spectroscopy techniques and instruments. It provides innovative laboratory services in order to deliver immediate results to potential customers of our instrumentation products. They are based in Charlottesville, Virginia,about two hours from Washington, DC. The BrightSpec Fourier transform molecular rotational resonance (FT-MRR) product platform is based on technology developed at the University of Virginia by Brooks Pate and his team, several of whom now work at BrightSpec. They offer FT-MRR product configurations for analytical chemistry and gas sensing in manufacturing process control, quality control, environmental monitoring, and formulation research. | $18.4M | Series C | Dec 14, 2022 |  |
| Bond Pet Foods | Bond Pet Foods makes pet food from real animal protein, without the animal by working with biotechnology. Bond Pet Foods develops meat proteins obtained from animal cells (no slaughter required) and natural microbes. It is fed a nutrient-rich broth of vitamins, sugars, and minerals in fermentation tanks, without the pharmaceuticals.Bond Pet Foodswas founded on 2015 and is headquartered in Boulder, Colorado. | $17.5M | Series A | Jun 24, 2022 |  |
| Meiogenix | Meiogenix is a biotech company developing breeding technologies to unlock the unexplored genetic diversity of organisms. Meiogenix expands the natural biodiversity and helps developing new products to address global food and industrial challenges. | $12.4M | Series A | Dec 14, 2021 |  |
| InterVenn | InterVenn focuses on the identification, quantification, and classification of Glycoproteomic and other PTM signals found in human blood and tissue for biomarker and target discovery. It specializes in the fields of biotechnology and life science. The company's VISTA is the first commercially available platform that can assess (serum orplasma) protein glycosylation in a site-specific manner, across thousands of peptides and glycopeptides.It was founded in 2017 and headquartered in Redwood City, California. | $201M | Series C | Aug 02, 2021 |  |
| InterVenn | InterVenn focuses on the identification, quantification, and classification of Glycoproteomic and other PTM signals found in human blood and tissue for biomarker and target discovery. It specializes in the fields of biotechnology and life science. The company's VISTA is the first commercially available platform that can assess (serum orplasma) protein glycosylation in a site-specific manner, across thousands of peptides and glycopeptides.It was founded in 2017 and headquartered in Redwood City, California. | $34M | Series B | Nov 16, 2020 |  |
| Ionpath | Ionpath is a developer of an ion beam imaging technology used to provide analysis of tissue biopsies. Its imaging technology surpasses light microscopy to analyze whether the tissues are fresh, frozen, or FFPE that enable healthcare providers to provide a diagnosis of cancer for improving human health. | $18M | Series B | Sep 24, 2020 |  |
| Tropic Biosciences | At Tropic Biosciences, They develop high-performing commercial varieties of tropical crops which promote grower wellbeing, consumer health, and improved sustainable environmental practices, using cutting edge non-GMO gene editing techniques. | $28.5M | Series B | Jun 04, 2020 |  |
| Intabio | Intabio is a Silicon Valley-based company developing analytical solutions to transform biotherapeutic development and manufacturing with products that provide early product quality characterization and profound efficiency gains across all stages of biopharmaceutical development and manufacturing.Intabio was founded in 2015 by Erik Gentalen andLena Wu and is based in Fremont, California, United States. | $18M | Series B | Feb 06, 2020 |  |
| InterVenn | InterVenn focuses on the identification, quantification, and classification of Glycoproteomic and other PTM signals found in human blood and tissue for biomarker and target discovery. It specializes in the fields of biotechnology and life science. The company's VISTA is the first commercially available platform that can assess (serum orplasma) protein glycosylation in a site-specific manner, across thousands of peptides and glycopeptides.It was founded in 2017 and headquartered in Redwood City, California. | $9.4M |  | Dec 12, 2018 |  |

10 of 27 investments shown.

## Co-investors
- [True Ventures](https://shizune.co/investors/profile/true-ventures) — VC Fund, 4 deals together
- [Aliment Capital](https://shizune.co/investors/profile/aliment-capital) — VC Fund, 3 deals together
- [Amplify Partners](https://shizune.co/investors/profile/amplify-partners) — VC Fund, 3 deals together
- [Anzu Partners](https://shizune.co/investors/profile/anzu-partner) — VC Fund, 3 deals together
- [Mission Bay Capital](https://shizune.co/investors/profile/mission-bay-capital-llc) — VC Fund, 3 deals together
- [Vertical Venture Partners](https://shizune.co/investors/profile/vertical-venture-partners) — VC Fund, 3 deals together

## About Genoa Ventures

VC Fund · San Francisco, United States

Genoa Ventures invests in early-stage life sciences technology companies. They fund entrepreneurs and companies looking to change the way science gets done with new tools and technologies. Sector focus areas include research tools, molecular diagnostics, synthetic biology, and industrial biology.Genoa Ventures was founded in 2014 by Jenny Rookeand is based in San Francisco, California, United States.

5 contacts available at Genoa Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| Jenny Rooke | Founder & Managing Director | https://shizune.co/investors/profile/jenny-rooke |
| Jonathan Burbaum | Venture Partner | https://shizune.co/investors/profile/jonathan-burbaum |
| Landon Merrill | principal | https://shizune.co/investors/profile/landon-merrill-ca74 |
| Paul Conley | Partner | https://shizune.co/investors/profile/dr-paul-conley |
| William (Bill) Hyun | Venture Partner | https://shizune.co/investors/profile/bill-hyun |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Jenny Rooke invest in?

Jenny Rooke invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Series A and Series B stage. Most of the 27 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Jenny Rooke last invest?

The most recent investment recorded for Jenny Rooke closed in Mar 2026. Shizune tracks 27 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co